Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03930680 · ClinicalTrials.gov registry record · Phase 1
Prevention of Heart Failure Induced by Doxorubicin With Early Administration of Dexrazoxane
A Phase 1 study of Degradation of Top2b and Top2a in Human by Dexrazoxane and Time Course and Degradation of Top2b in Human by Dexrazoxane, sponsored by University of Arkansas.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT03930680 is a Phase 1 study of Degradation of Top2b and Top2a in Human by Dexrazoxane and Time Course and Degradation of Top2b in Human by Dexrazoxane that has completed, run by University of Arkansas. The registered enrollment target is 25 participants. The trial reports 1 study location across 1 state.
The verdict
NCT03930680, a Phase 1 study of Degradation of Top2b and Top2a in Human by Dexrazoxane and Time Course and Degradation of Top2b in Human by Dexrazoxane, has completed, sponsored by University of Arkansas.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research study is to determine whether early administration of Dexrazoxane prevents Doxorubicin induced cardiotoxicity.
Conditions Studied
Interventions
- DRUG Dexrazoxane
Study Locations (1)
Arkansas
- University of Arkansas for Medical Sciences - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2021-09-14 |
| Est. Completion | 2025-06-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03930680
The ClinicalTrials.gov registry entry for NCT03930680 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Arkansas, which has 318 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Degradation of Top2b and Top2a in Human by Dexrazoxane appearing as the primary indexed condition, and to 1 intervention - of which Dexrazoxane is the first listed.
NCT03930680 reports 1 study location spanning 1 distinct geographic area - top geographies include Arkansas.
Frequently Asked Questions
What is clinical trial NCT03930680 about?
NCT03930680 is a clinical study titled "Prevention of Heart Failure Induced by Doxorubicin With Early Administration of Dexrazoxane". The purpose of this research study is to determine whether early administration of Dexrazoxane prevents Doxorubicin induced cardiotoxicity.
What is the current status of trial NCT03930680?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2021-09-14. Estimated completion is 2025-06-11.
What conditions does trial NCT03930680 study?
This clinical trial studies the following conditions: Degradation of Top2b and Top2a in Human by Dexrazoxane, Time Course and Degradation of Top2b in Human by Dexrazoxane, Effects of Dexrazoxane on Healthy Human.
What interventions are being tested in trial NCT03930680?
The interventions under investigation include: Dexrazoxane (DRUG).
Who is sponsoring clinical trial NCT03930680?
This trial is sponsored by University of Arkansas, which has 318 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03930680 being conducted?
This trial has 1 study location across Arkansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Degradation of Top2b and Top2a in Human by Dexrazoxane
All registered trials for this condition
Time Course and Degradation of Top2b in Human by Dexrazoxane
All registered trials for this condition
Arkansas
All trials with a study site in Arkansas
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.